France vs Tajikistan: Access to anti-retroviral drugs, female
France
93.0%
in 2022
Tajikistan
95.0%
in 2024
France rank
22nd
Tajikistan rank
19th
Access to anti-retroviral drugs, female over time
- France
- Tajikistan
How they compare
Tajikistan currently reports 95.0% against 93.0% in France, a difference of 2.0%.
Across all 23 years both countries report, France has been ahead every year.
France ranks 22nd and Tajikistan ranks 19th of 141 countries.
France has averaged higher in every one of the 3 decades both report.
Head to head by decade
| Decade | France | Tajikistan | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 81.2% | 0.7% | 80.5% | France |
| 2010s | 90.4% | 29.8% | 60.6% | France |
| 2020s | 91.7% | 78.0% | 13.7% | France |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher access to anti-retroviral drugs, female, France or Tajikistan?
- Tajikistan, at 95.0% against 93.0% in France as of 2024.
- What is the difference in access to anti-retroviral drugs, female between France and Tajikistan?
- 2.0%, with Tajikistan ahead.
- How many years of comparable data are there for France and Tajikistan?
- 23 years are reported by both, from 2000 to 2022.
- How do France and Tajikistan rank globally for access to anti-retroviral drugs, female?
- France ranks 22nd and Tajikistan ranks 19th of 141 countries.
- Where does this data come from?
- UNAIDS estimates, published as Access to anti-retroviral drugs, female (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
The percentage of adult females living with HIV who are receiving antiretroviral therapy.